190 related articles for article (PubMed ID: 33742144)
21. Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer.
Wang J; Wang H; Liu A; Fang C; Hao J; Wang Z
Oncotarget; 2015 Aug; 6(23):19456-68. PubMed ID: 26062441
[TBL] [Abstract][Full Text] [Related]
22. Double genetic disruption of lactate dehydrogenases A and B is required to ablate the "Warburg effect" restricting tumor growth to oxidative metabolism.
Ždralević M; Brand A; Di Ianni L; Dettmer K; Reinders J; Singer K; Peter K; Schnell A; Bruss C; Decking SM; Koehl G; Felipe-Abrio B; Durivault J; Bayer P; Evangelista M; O'Brien T; Oefner PJ; Renner K; Pouysségur J; Kreutz M
J Biol Chem; 2018 Oct; 293(41):15947-15961. PubMed ID: 30158244
[TBL] [Abstract][Full Text] [Related]
23. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A.
Lu H; Li X; Luo Z; Liu J; Fan Z
Mol Cancer Ther; 2013 Oct; 12(10):2187-99. PubMed ID: 23920275
[TBL] [Abstract][Full Text] [Related]
26. E2F1-Induced FTH1P3 Promoted Cell Viability and Glycolysis Through miR-377-3p/LDHA Axis in Laryngeal Squamous Cell Carcinoma.
Zhao L; Zheng Y; Zhang L; Su L
Cancer Biother Radiopharm; 2022 May; 37(4):276-286. PubMed ID: 33571038
[No Abstract] [Full Text] [Related]
27. Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells.
Muramatsu H; Sumitomo M; Morinaga S; Kajikawa K; Kobayashi I; Nishikawa G; Kato Y; Watanabe M; Zennami K; Kanao K; Nakamura K; Suzuki S; Yoshikawa K
Oncol Rep; 2019 Jul; 42(1):224-230. PubMed ID: 31180564
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
Naz S; Leiker AJ; Choudhuri R; Preston O; Sowers AL; Gohain S; Gamson J; Mathias A; Van Waes C; Cook JA; Mitchell JB
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1295-1305. PubMed ID: 33838214
[TBL] [Abstract][Full Text] [Related]
29. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
30. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Coan JP; Pearson HE; Bahrar H; Fowler TL; Bednarz BP; Saha S; Yang D; Gill PS; Lingen MW; Saloura V; Villaflor VM; Salgia R; Kimple RJ; Wheeler DL
Clin Cancer Res; 2015 Jun; 21(11):2601-12. PubMed ID: 25767293
[TBL] [Abstract][Full Text] [Related]
31. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of LDHA suppresses cell proliferation and increases mitochondrial apoptosis via the JNK signaling pathway in cervical cancer cells.
Zhang W; Wang C; Hu X; Lian Y; Ding C; Ming L
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35191522
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
34. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.
Xie H; Valera VA; Merino MJ; Amato AM; Signoretti S; Linehan WM; Sukhatme VP; Seth P
Mol Cancer Ther; 2009 Mar; 8(3):626-35. PubMed ID: 19276158
[TBL] [Abstract][Full Text] [Related]
35. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Chen X; Cao Y; Sedhom W; Lu L; Liu Y; Wang H; Oka M; Bornstein S; Said S; Song J; Lu SL
Mol Oncol; 2020 Jan; 14(1):139-158. PubMed ID: 31600013
[TBL] [Abstract][Full Text] [Related]
36. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.
Jiang Y; Cao W; Wu K; Qin X; Wang X; Li Y; Yu B; Zhang Z; Wang X; Yan M; Xu Q; Zhang J; Chen W
J Exp Clin Cancer Res; 2019 Aug; 38(1):365. PubMed ID: 31429766
[TBL] [Abstract][Full Text] [Related]
37. Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.
Elkashty OA; Abu Elghanam G; Su X; Liu Y; Chauvin PJ; Tran SD
Carcinogenesis; 2020 Jun; 41(4):458-466. PubMed ID: 31742606
[TBL] [Abstract][Full Text] [Related]
38. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
39. Overexpression of ZEB2-AS1 promotes epithelial-to-mesenchymal transition and metastasis by stabilizing ZEB2 mRNA in head neck squamous cell carcinoma.
Diao P; Ge H; Song Y; Wu Y; Li J; Li Z; Yang J; Wang Y; Cheng J
J Cell Mol Med; 2019 Jun; 23(6):4269-4280. PubMed ID: 30950191
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
